December 8, 2019

Regeneron Reports Excellent Results For REGN5458

Regeneron Pharmaceuticals announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. REGN5458 is designed to bind to BCMA on multiple myeloma cells

by Lance Jepsen

Stock Trading

December 8, 2019

Autolus Therapeutics Awesome Data Proves CART Therapy Is the Future

Autolus Therapeutics (AUTL) reported awesome data from their human CAR T clinical trial. If there was any doubt that CAR T therapy is the future, let that doubt be put

by Lance Jepsen

Stock Trading

December 8, 2019

Bluebird Bio Incredible Sickle Cell Disease Data Release at ASH

Bluebird Bio released incredible clinical data this weekend at ASH for people suffering with sickle cell disease. bluebird bio, Inc. (Nasdaq: BLUE) announced new data from its ongoing Phase 1/2 HGB-206

by Lance Jepsen

Stock Trading

December 8, 2019

TGTX Stock Set To Soar On Blockbuster ASH Data

TGTX stock could soar in pre-marketing trading on Monday, December 9, 2019, after the company reported stellar clinical trial data. TG Therapeutics announced triple therapy data from the Phase I/II study

by Lance Jepsen

Stock Trading

December 7, 2019

BLUE Stock Runs In AH On Dec 6 As Trial Met Endpoints

BLUE stock closed up 9.4 percent in after-hours trading on December 6, 2019, after the company reported Phase 2 KarMMa study results. BLUE stock in the 15-minute time frame, surges higher

by Lance Jepsen

Stock Trading

December 5, 2019

SRRA Running Up Ahead of ASH

SRRA stock is running up ahead of ASH but what really got the stock exploding 12% in after-hours trading on December 5, 2019, is an Oppenheimer analyst. SRRA stock ran up

by Lance Jepsen

Stock Trading

December 5, 2019

BLRX Stock Moving In Trial Data Release

BLRX stock is attracting buyer interest right before market open on December 5, 2019, after the company released clinical trial data. BioLineRx announced preliminary data from the triple combination arm of the

by Lance Jepsen

Stock Trading

December 4, 2019

AUPH Stock Explodes 119% In After-hours Trading

AUPH stock exploded 119% in after-hours trading on December 4, 2019, after the company reported posted Phase 3 clinical data. AUPH stock in the 15-minute time frame exploded 119% higher in

by Lance Jepsen

Stock Trading

December 4, 2019

PTI Stock Up On Clinical Data Coming By Year End

PTI stock closed up 5% on December 4, 2019, on positive Cantor Fitzgerald comments. Analyst Kristen Kluska of Cantor Fitzgerald assumed coverage of Proteostasis Therapeutics (PTI) stock with an Overweight rating

by Lance Jepsen

Stock Trading

December 4, 2019

PTGX Stock Moving In Pre-market Trading December 4 2019

The buying of PTGX stock continues in pre-market trading on December 4, 2019. Nomura Instinet analyst Christopher Marai says he's an "aggressive" buyer of Protagonist Therapeutics following yesterday's selloff. The

by Lance Jepsen

« Older Articles